The partnership will utilize Ginkgo's bioengineering platform to express and screen thousands of SARS-CoV-2 antibody candidates. It will also adapt and scale Totient's tertiary lymphoid structures (TLSs), which were designed for oncology and autoimmunity solutions.

The TLS platform will reconstruct antibodies from bronchoalveolar lavage fluid samples of patients with COVID-19 at Avera McKennan Hospital in South Dakota. Gingko and Totient hope to identify at least one patient-derived neutralizing antibody to advance into further studies, with the ultimate goal of developing a high-affinity therapeutic.

New AI-based company targets discovery of new protein-based therapeutics
Flagship Pioneering has launched Generate Biomedicines, a new company that will use its machine learning-powered platform for the rapid discovery of new...

Axon's COVID-19 vaccine shows promise for elderly population
Clinical-stage biotechnology company Axon Neuroscience has touted results from a preclinical trial for its COVID-19 vaccine candidate.

Pfizer, BioNTech release preclinical data, talk with EU about COVID-19 vaccine
Preclinical data have demonstrated the ability of BNT162b2, Pfizer and BioNTech's COVID-19 vaccine, to protect against infection. The companies are also...

Protein engineering creates highly potent experimental SARS-CoV-2 vaccine
A bioengineering technique that utilizes various naturally occurring sequences and de novo design of messenger RNA (mRNA) components was applied to develop...

Detecting SARS-CoV-2 in blood may be early indicator of severe disease
A blood test that measures SARS-CoV-2 RNA when patients are admitted to the hospital with COVID-19 symptoms can be a powerful diagnostic tool to predict...